Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1

Breast Cancer Research and Treatment

Volumn 98, Issue 2, 2006, Pages 121-132

  Chen, Chiachen ^a   Chang, Yuan Ching ^b,c   Liu, Chien Liang ^b,c   Chang, King Jen ^d   Guo, Ing Cherng ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Breast cancer; c Myc; Cyclin D1; Leptin; Leptin receptor; p21 WAF1 CIP1; Tumor suppressor p53

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTROGEN; JANUS KINASE 2; JANUS KINASE INHIBITOR; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYC PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NITROBLUE TETRAZOLIUM; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN P53; WORTMANNIN;

ARTICLE; AUTOCRINE EFFECT; AUTOREGULATION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CELL ASSAY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOTHESIS; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; GENES, MYC; HUMANS; LEPTIN; MAP KINASE KINASE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33745886839     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9139-y     Document Type: Article

References (57)

1. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quiros JR, Martinez C, Tormo MJ, Wirfalt E, Berglund G, Hallmans G, Key TJ, Reeves G, Bingham S, Norat T, Biessy C, Kaaks R, Riboli E: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111: 762-771, 2004
2. Dumitrescu RG, Cotarla I: Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med 9: 208-221, 2005
3. Kroenke CH, Chen WY, Rosner B, Holmes MD: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23: 1370-1378, 2005
4. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C: Endogenous Hormones Breast Cancer Collaborative Group: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95: 1218-1226, 2003
5. McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, Gilliland F, Stanczyk FZ, Yasui Y, Ballard-Barbash R: Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21: 1961-1966, 2003
6. Misso ML, Jang C, Adams J, Tran J, Murata Y, Bell R, Boon WC, Simpson ER, Davis SR: Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause 12: 210-215, 2005
7. Van Gaal LF, Wauters MA, Mertens IL, Considine RV, De Leeuw IH: Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord 23(Suppl 1): 29-36, 1999
8. Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C, Mussa A: Leptin expression in colorectal and breast cancer patients. Int J Mol Med 5: 421-426, 2000
9. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, Juneja SC, Grande JP, Maihle NJ: Genetically obese MMTV-TGF-alpha/Lep(ob) Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 77: 205-215, 2003
10. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ: Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 229: 182-193, 2004
11. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994
12. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, Tepper RI: Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271, 1995
13. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, Friedman JM: Abnormal splicing of the leptin receptor in diabetic mice. Nature 379: 632-635, 1996
14. Fei H, Okano HJ, Li C, Lee GH, Zhao C, Darnell R, Friedman JM: Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA 94: 7001-7005, 1997
15. Hegyi K, Fülöp K, Kovács K, Tóth S, Falus A: Leptin-induced signal transduction pathways. Cell Biol Int 28: 159-169, 2004
16. Smith-Kirwin SM, O'Connor DM, De Johnston J, Lancey ED, Hassink SG, Funanage VL: Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab 83: 1810-1813, 1998
17. O'Brien SN, Welter BH, Price TM: Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun 259: 695-698, 1999
18. Ishikawa M, Kitayama J, Nagawa H: Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10: 4325-4331, 2004
19. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y: Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 293: 622-628, 2002
20. Garofalo C, Sisci D, Surmacz E: Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin Cancer Res 10: 6466-6475, 2004
21. Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, Wu H, Wu G, Wang X, Shang Y: Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 64: 5870-5875, 2004
22. Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94: 1704-1711, 2002
23. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J: Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 188: 219-226, 2002
24. Vona-Davis L, Skinner H, Jackson B, Riggs D, Somasundar P, McFadden DW: Leptin activates MAPK signaling in human breast and prostate cancer. J Surg Res 114: 300-301, 2003
25. Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, Jamali M, Cooper DR, Yasuda K: Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta 1592: 107-116, 2002
26. Onuma M, Bub JD, Rummel TL, Iwamoto Y: Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278: 42660-42667, 2003
27. Somasundar P, Frankenberry KA, Skinner H, Vedula G, McFadden DW, Riggs D, Jackson B, Vangilder R, Hileman SM, Vona-Davis LC: Prostate cancer cell proliferation is influenced by leptin. J Surg Res 118: 71-81, 2004
28. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH: Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21: 7680-7689, 2002
29. Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002
30. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021, 2001
31. Somasundar P, Yu AK, Vona-Davis L, McFadden DW: Differential effects of leptin on cancer in vitro. J Surg Res 113: 50-55, 2003
32. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, Seiser C: The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 23: 2669-2679, 2003
33. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, Andò S: Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278: 28668-28676, 2003
34. O'Neil JS, Burow ME, Green AE, McLachlan JA, Henson MC: Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors α and β. Mol Cell Endocrinol 176: 67-75, 2001
35. Somasundar P, McFadden DW, Hileman SM, Vona-Davis L: Leptin is a growth factor in cancer. J Surg Res 116: 337-349, 2004
36. Marttunen MB, Andersson S, Hietanen P, Karonen SL, Koistinen HA, Koivisto VA, Tiitinen A, Ylikorkala O: Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients. Maturitas 35: 175-179, 2000
37. Lambrinoudaki I, Christodoulakos G, Panoulis C, Botsis D, Rizos D, Augoulea A, Creatsas G: Determinants of serum leptin levels in healthy postmenopausal women. J Endocrinol Invest 26: 1225-1230, 2003
38. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D: Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 11: 383-388, 2000
39. Rose DP, Gilhooly EM, Nixon DW: Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). Int J Oncol 21: 1285-1292, 2002
40. Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, Vanderkerken K: Specific roles for the PI3K and MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 90: 1076-1083, 2004
41. Duan C, Li M, Rui L: SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J Biol Chem 279: 43684-43691, 2004
42. Sahu A: Minireview: a hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 145: 2613-2620, 2004
43. Fernando RI, Wimalasena J: Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15: 3266-3284, 2004
44. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML, Andò S: Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 279: 19908-19915, 2004
45. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B: Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229: 161-173, 2005
46. Sutherland RL, Musgrove EA: Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9: 95-104, 2004
47. Deming SL, Nass SJ, Dickson RB, Trock BJ: C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83: 1688-1695, 2000
48. Liao DJ, Natarajan G, Deming SL, Jamerson MH, Johnson M, Chepko G, Dickson RB: Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene 19: 1307-1317, 2000
49. Oswald F, Lovec H, Moroy T, Lipp M: E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene 9: 2029-2036, 1994
50. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL: Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 62: 3126-3131, 2002
51. Mitchell KO, el-Deiry WS: Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 10: 223-230, 1999
52. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993
53. Mukherjee S, Conrad SE: c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280: 17617-17625, 2005
54. Seoane J, Le HV, Massague J: Myc suppression of the p21(Cipl) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729-734, 2002
55. Vaque JP, Navascues J, Shiio Y, Laiho M, Ajenjo N, Mauleon I, Matallanas D, Crespo P, Leon J: Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway. J Biol Chem 280: 1112-1122, 2005
56. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002
57. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993